

# Market Analysis of 20<sup>th</sup> Annual Conference on Nephrology and Urology

Behzad Saberi

## Importance and Scope of Nephrology

The global nephrology devices market size was founded as USD 18.03 billion in 2016 and is predicted to develop at a CAGR of 7.1% over the forecast period. Increase in ubiquity of Kidney failure and end-stage kidney diseases among people that has resulted in clinical necessity for the devices to improve the existing patient outcomes & restraint long-term prices associated with treatment of Kidney Diseases.

Also, extending geriatric population base, that is extremely susceptibility to these diseases, is anticipated to spur demand within the coming years. According to a research published in Medscape, kidney disease is one in all the most important causes for prime death rate in U.S. As mentioned in an analysis published in NCBI, end-stage renal disease is a major cost driver in most healthcare systems across developed economies. As a result, rising awareness concerning renal replacements within these economies is likely to supply profitable growth opportunities in the market.

The current market focuses on the technological advancements in devices like extracorporeal, percutaneous way and inclusion of prosthetics in urology. These technologies have resulted in improved capacities in urinary organ and urinary stone management and cater to larger patient volumes due to reduced treatment period and recovery time. These technologies conjointly scale back the chance of recurrence of stone formation and are being progressively incorporated in pediatric urology.

Dialysis equipment held the dominant revenue share in the nephrology and urology devices market as of 2015.

The Asia Pacific market is anticipated to witness moneymaking growth within the returning years because of increasing attention expenditure levels, rising awareness associated with urinary organ and tract disorders, and rising attention facilities within the region. Moreover, pressing want for development of latest systems and replacement and upgrading existing medical infrastructure square measure alternative factors attributed to growing demand for these devices.

## Bladder Cancer Cases

Bladder Cancer Therapeutics Market to Perceive Substantial Growth Estimated by Top Players Sanofi S.A., F. Hoffmann-La Roche AG, Novartis, Pfizer, Eli Lilly and Co.

As per stats released by the International Agency for Research on Cancer (IARC), 59% of bladder cancer cases are observed in developed countries, with Belgium reporting the highest number of bladder cancer cases.

As per stats released by Cancer Research UK—a charity involved in cancer research and development—here were around 10,100 new cases reported in the U.K. in 2014. Bladder cancer accounts for around 3% of all new cancer cases reported in the U.K. As per a study by the American Society of Clinical Oncology (ASCO), incidence rate of the disease has decreased by around 12% in the U.K. in the recent past.

According a study by Cancer Research Institute, bladder cancer is more prevalent among men than women. Around 77,000 new cases were diagnosed in the U.S. in 2016, leading to 16,000 deaths. Continuous advancements in clinical research resulted into increased survival rate of people suffering from bladder cancer, which is around 77% observed in last

few years. As per the stats of American Cancer Society, bladder cancer accounts for 5% of all new cancer cases in the U.S.

Some are the major reasons behind bladder cancer are unhealthy habits. Smoking is a major cause along with that continuous exposure of industrial chemicals, drinking water with high level of arsenic, family history of bladder cancer, and long-term use of urinary catheters are the other causes of bladder cancer. In Africa and Middle East schistosomiasis and infested water are the leading cause of bladder cancer.

North America holds major share in the global bladder cancer therapeutics market, followed by Europe due to advanced treatments, developed economy, and easy access to advanced healthcare facilities. The market in APAC region will witness high growth rate in the near future, due to increasing per capita income, developing economy, government initiatives on improving healthcare infrastructure, growing FDI in healthcare, and rapidly increasing aging population. As per stats released by the Department of Industrial Policy and Promotion (DIPP), the healthcare sector in India witness FDI worth US\$ 4.09 billion between April 2000 and September 2016. Also, medical tourism in the region is a flourishing business, due to easy access to high-quality low-cost treatment option. According to data released by the India Brand Equity Foundation (IBEF)—a Trust established by the Department of Commerce, Ministry of Commerce and Industry, Government of India - the medical tourism industry in India rakes in US\$ 3 billion each year. This creates a highly conducive environment for growth of the bladder cancer therapeutics market in the region.

## Renal Dialysis Market Regional Analysis

On regional basis, international Kidney dialysis market is segmented as North America, Europe, Asia Pacific and Middle East and Africa. North America has the most important marketplace for the world renal dialysis market. Increasing patient stricken by renal diseases in North America is increasing endlessly which is the major factor for the expansion of the market. Europe and Asia Pacific have nearly similar marketplace for renal dialysis however the expansion rate of Asia Pacific renal dialysis market is higher. Middle east and Africa contribute the smallest amount marketplace for the renal dialysis market.

## Key Players for Global Renal Dialysis Market

Baxter International Inc. (US), Fresenius Medical Care (German), DaVita Healthcare Partners Inc. (US), B.Braun Melsungen AG (Germany), Medical Care AG & Co., Gambro AB (Sweden), Nipro diagnostic Inc. (US), Diaverum Deutschland GmbH (Germany), KGaA (Germany), Covidien (Ireland), Nikkiso Co. Ltd. (Japan), Asahi Kasei Corporation (Japan), NxStage Medical, Inc. (U.S.), Fresenius Medical Care, Boston Scientific, C.R. Bard Inc., Cook Medical, and Dornier MedTech.

The Global Market for Kidney Disease and failure treatment will rise from \$39.4 billion in 2016 to approx. \$45.6 billion by 2021, with a Compound Annual Growth Rate of 3.0%

Asia-Pacific leads the market with a 43 per cent share, followed by North America and Europe

Behzad Saberi

Lecturer, University of Eastern Finland, Finland, E-mail: sab64b@yahoo.com

The recent report on Nephrology and Urology released from Global Data has pointed on how the outbreak of Diabetes and Hypertension unify with aging population is driving the investment to meet the patient needs

In 2016, renal dialysis equipment accounted for over 55 per cent of the market value, at over \$17 billion, and this is expected to grow to over \$26 billion by 2026.

In Japan, the market for renal dialysis equipment will increase from \$5 billion in 2015 to over \$11 billion by 2022, representing a Compound Annual Growth Rate (CAGR) of 3.48%.

Products manufactured by the industry related [Nephrology](#) Research and its Market Value in Japan:

- Japanese Society of Nephrology
- The Japan Diabetes Society
- International Kidney Evaluation Association Japan
- The University of Tokyo Hospital

Prevalence of Chronic [Kidney Disease](#), by Country:

